Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18744124 | PHOTOSYSTEM I-HYDROGENASE CHIMERAS FOR HYDROGEN PRODUCTION | June 2024 | March 2026 | Allow | 21 | 1 | 1 | No | No |
| 18657159 | Heat Resistant Biopesticide And A Method Of Preparing The Same | May 2024 | June 2025 | Allow | 13 | 2 | 1 | Yes | No |
| 18657101 | ENGINEERED GALACTOSE OXIDASE VARIANT ENZYMES | May 2024 | July 2025 | Allow | 15 | 1 | 1 | No | No |
| 18655701 | PEROXIDASE ACTIVITY TOWARDS 10-ACETYL-3,7-DIHYDROXYPHENOXAZINE | May 2024 | October 2025 | Allow | 17 | 2 | 1 | Yes | No |
| 18638690 | BETA-GLYCOSIDASE SS-BGL MUTANT FOR MODIFYING GINSENOSIDE AND APPLICATION THEREOF | April 2024 | January 2025 | Allow | 9 | 2 | 1 | No | No |
| 18611058 | Bacterium And Obtaining Method And Application Thereof | March 2024 | January 2026 | Allow | 22 | 2 | 1 | No | No |
| 18598466 | Cleaning Compositions Comprising Enzymes | March 2024 | January 2026 | Abandon | 22 | 2 | 1 | Yes | No |
| 18598872 | PROTEASE COMPOSITIONS AND METHODS OF USE THEREOF | March 2024 | October 2025 | Abandon | 19 | 1 | 1 | No | No |
| 18590655 | LACHNOSPIRACEAE SP. CAS12A MUTANTS WITH ENHANCED CLEAVAGE ACTIVITY AT NON-CANONICAL TTTT PROTOSPACER ADJACENT MOTIFS | February 2024 | August 2025 | Allow | 18 | 2 | 1 | Yes | No |
| 18436552 | FEED COMPOSITION SUPPLEMENTED WITH A PROTEASE COMBINATION | February 2024 | April 2025 | Abandon | 14 | 0 | 1 | No | No |
| 18424815 | ENGINEERED STABLE NUCLEIC ACID-GUIDED NUCLEASES | January 2024 | September 2024 | Abandon | 7 | 1 | 1 | No | No |
| 18411153 | LIQUID FORMULATION OF ALPHA-AMYLASE | January 2024 | May 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18403265 | ENGINEERED URIDINE PHOSPHORYLASE VARIANT ENZYMES | January 2024 | June 2025 | Allow | 17 | 1 | 1 | No | No |
| 18503542 | ENGINEERED DEOXYRIBOSE-PHOSPHATE ALDOLASES | November 2023 | July 2025 | Allow | 20 | 2 | 1 | No | No |
| 18504010 | TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE VARIANTS AND USES THEREOF | November 2023 | June 2025 | Allow | 19 | 2 | 1 | Yes | No |
| 18497758 | VARIANTS OF CHYMOSIN WITH IMPROVED MILK-CLOTTING PROPERTIES | October 2023 | August 2025 | Abandon | 22 | 2 | 1 | No | No |
| 18553072 | ENZYMATIC METHOD FOR PRODUCING L-GLUFOSINATE AND ITS PHOSPHOESTERS | September 2023 | September 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18465961 | ENCAPSULATION OF DUAL-ENZYME COMPOSITION FOR PREVENTING, TREATING AND/OR ALLEVIATING VEISALGIA AND SYMPTOMS ASSOCIATED THEREWITH | September 2023 | October 2024 | Allow | 13 | 1 | 1 | Yes | No |
| 18459797 | ENGINEERED TRANSAMINASE POLYPEPTIDES | September 2023 | February 2025 | Allow | 17 | 1 | 1 | Yes | No |
| 18274770 | METHOD AND SPECIAL COMPLEX ENZYME FOR HYDROLYZING GALACTOMANNAN (GM) TO PREPARE SMALL-MOLECULE GM AND GALACTOMANNAN OLIGOSACCHARIDE (GMOS) | July 2023 | April 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18341792 | GDSL LIPASE, GENETICALLY-ENGINEERED BACTERIA AND APPLICATION THEREOF | June 2023 | January 2025 | Allow | 19 | 2 | 0 | Yes | No |
| 18039688 | METHODS FOR THE PURIFICATION OF REFOLDED FC-PEPTIDE FUSION PROTEIN | May 2023 | November 2025 | Allow | 29 | 1 | 0 | No | No |
| 18316993 | PRENYLTRANSFERASE VARIANTS AND METHODS FOR PRODUCTION OF PRENYLATED AROMATIC COMPOUNDS | May 2023 | November 2025 | Abandon | 30 | 0 | 1 | No | No |
| 18300251 | METHOD OF IMPROVING ACID DECARBOXYLASE ACTIVITY IN VITRO UNDER ALKALINE PH | April 2023 | March 2025 | Allow | 23 | 1 | 1 | No | No |
| 18031036 | METHOD OF PURIFICATION OF RECOMBINANTLY-PRODUCED RSV PROTEINS IN TRIMERIC FORM | April 2023 | March 2026 | Allow | 35 | 1 | 0 | No | No |
| 18247957 | MUTATIONS FOR IMPROVING ACTIVITY AND THERMOSTABILITY OF PETASE ENZYMES | April 2023 | February 2026 | Allow | 35 | 1 | 1 | No | No |
| 18123840 | RECOMBINANT HOST CELLS FOR THE PRODUCTION OF MALONATE | March 2023 | August 2025 | Abandon | 29 | 1 | 1 | No | No |
| 18245378 | NOVEL SERINE PROTEASES | March 2023 | February 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18022429 | SYSTEMS, DEVICES AND METHODS FOR DETERMINING MOST PROBABLE NUMBER IN BIOLOGICAL SAMPLE ANALYSIS | February 2023 | October 2025 | Allow | 31 | 1 | 0 | No | No |
| 18006563 | CARBON MONOXIDE DEHYDROGENASE HAVING EXCELLENT OXYGEN RESISTANCE AND ENZYME ACTIVITY, AND USE THEREOF | January 2023 | September 2025 | Allow | 31 | 1 | 0 | No | No |
| 18157226 | METHOD FOR PRODUCING HYDROXY-L-PIPECOLIC ACID | January 2023 | October 2024 | Allow | 21 | 2 | 1 | Yes | No |
| 18154475 | ENGINEERED PHENYLALANINE AMMONIA LYASE POLYPEPTIDES | January 2023 | April 2024 | Abandon | 15 | 0 | 1 | No | No |
| 18154388 | ENGINEERED PHENYLALANINE AMMONIA LYASE POLYPEPTIDES | January 2023 | May 2024 | Abandon | 16 | 0 | 1 | Yes | No |
| 18004327 | METHOD FOR THE FERMENTATIVE PRODUCTION OF GUANIDINOACETIC ACID | January 2023 | April 2024 | Allow | 16 | 3 | 0 | Yes | No |
| 18091687 | NOVEL HYDROLASE AND METHOD FOR PRODUCING (1S,2S)-1-ALKOXYCARBONYL-2-VINYLCYCLOPROPANE CARBOXYLIC ACID USING SAME | December 2022 | November 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 18087169 | APPLYING OPTOGENETIC AMPLIFIER CIRCUITS FOR MULTI-PHASE LIGHT CONTROLLED MICROBIAL FERMENTATIONS | December 2022 | September 2025 | Allow | 33 | 1 | 1 | No | No |
| 18066303 | FUCOSYLATION-DEFICIENT CELLS | December 2022 | March 2024 | Allow | 15 | 1 | 1 | No | No |
| 18063732 | Thermobifida fusca cutinase mutant and its soluble expression method | December 2022 | March 2026 | Abandon | 39 | 1 | 1 | No | No |
| 18050446 | VARIANTS OF PORCINE TRYPSIN | October 2022 | November 2023 | Allow | 13 | 0 | 1 | Yes | No |
| 18049055 | RECOMBINANT YEAST HOST CELL EXPRESSING AN HYDROLASE | October 2022 | March 2024 | Abandon | 17 | 1 | 1 | No | No |
| 18047824 | COMPOSITIONS OF PROKARYOTIC PHENYLALANINE AMMONIA-LYASE VARIANTS AND METHODS OF USING COMPOSITIONS THEREOF | October 2022 | January 2025 | Abandon | 27 | 1 | 1 | No | No |
| 18046895 | ENGINEERED DNA POLYMERASE VARIANTS | October 2022 | June 2024 | Allow | 20 | 1 | 1 | No | No |
| 17916695 | METHODS FOR PRODUCTION OF OLIGOSACCHARIDES | October 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17916510 | CARBOXYESTERASE POLYPEPTIDES FOR KINETIC RESOLUTION | September 2022 | December 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17936744 | NUCLEIC ACID POLYMERASE VARIANTS, KITS AND METHODS FOR TEMPLATE-INDEPENDENT RNA SYNTHESIS | September 2022 | June 2025 | Abandon | 33 | 1 | 1 | No | No |
| 17936610 | MUTATED SULFOTRANSFERASES AND USES THEREOF | September 2022 | June 2025 | Abandon | 32 | 2 | 1 | No | No |
| 17934003 | BACILLUS SUBTILIS SUBSPECIES | September 2022 | January 2026 | Abandon | 40 | 2 | 0 | No | Yes |
| 17947195 | DUAL-ENZYME COMPOSITION FOR PREVENTING, TREATING AND/OR ALLEVIATING VEISALGIA AND SYMPTOMS ASSOCIATED THEREWITH | September 2022 | July 2023 | Allow | 10 | 2 | 0 | No | No |
| 17932184 | GENE RECOMBINANT VECTOR, GENETICALLY ENGINEERED STRAIN AND PREPARATION METHOD OF COLLAGENASE | September 2022 | June 2023 | Allow | 9 | 1 | 0 | Yes | No |
| 17931003 | ENGINEERED GALACTOSE OXIDASE VARIANT ENZYMES | September 2022 | February 2024 | Allow | 17 | 2 | 1 | No | No |
| 17929173 | XYLANASES FOR SOLUBILISING ARABINOXYLAN-CONTAINING MATERIAL | September 2022 | January 2024 | Allow | 16 | 2 | 1 | No | No |
| 17822587 | BLENDS CONTAINING PROTEASES | August 2022 | January 2026 | Allow | 60 | 2 | 1 | No | No |
| 17891482 | ENGINEERED CYANOBACTERIA WITH ENHANCED UV TOLERANCE | August 2022 | February 2025 | Allow | 30 | 2 | 1 | Yes | No |
| 17799049 | MANNANASE VARIANTS | August 2022 | January 2026 | Allow | 41 | 2 | 1 | Yes | No |
| 17818270 | RECOMBINANT YEAST EXPRESSING HETEROLOGOUS STL1 PROTEIN | August 2022 | July 2023 | Abandon | 11 | 1 | 0 | No | No |
| 17879663 | Materials and Methods for Producing Alkaloids | August 2022 | June 2024 | Allow | 22 | 1 | 1 | No | No |
| 17878858 | BIOSYNTHETIC PRODUCTION OF PSILOCYBIN AND RELATED INTERMEDIATES IN RECOMBINANT ORGANISMS | August 2022 | July 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17811933 | METHOD FOR PRODUCING TREHALOSE EMPLOYING A TREHALOSE PHOSPHORYLASE VARIANT | July 2022 | June 2025 | Allow | 35 | 1 | 1 | No | No |
| 17811776 | METHODS AND MICROORGANISMS FOR THE FERMENTATION OF METHANE TO MULTI-CARBON COMPOUNDS | July 2022 | October 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17811801 | Cleaning Compositions comprising Enzymes | July 2022 | September 2023 | Abandon | 15 | 0 | 1 | No | No |
| 17811701 | Cleaning Compositions comprising Enzymes | July 2022 | February 2024 | Allow | 19 | 2 | 1 | Yes | No |
| 17811447 | Novel Selection Marker for Cell Transfection and Protein Production | July 2022 | September 2024 | Allow | 26 | 3 | 1 | Yes | No |
| 17852836 | Isolated or Engineered Polypeptides, Microorganisms as well as Method for Synthesizing Phenolic Phytochemical Phosphate Derivatives using the Polypeptides or Microorganisms | June 2022 | May 2025 | Abandon | 35 | 3 | 1 | Yes | No |
| 17758042 | RECOMBINANT BACTERIA FOR PRODUCING DE-EPOXIDIZED EPOTHILONE B AND USE THEREOF | June 2022 | September 2025 | Allow | 38 | 1 | 1 | No | No |
| 17786720 | STABILIZATION OF OXIDASES BY DRYING UNDER REDUCED PARTIAL OXYGEN PRESSURE | June 2022 | January 2026 | Abandon | 43 | 1 | 1 | No | No |
| 17784775 | MICROORGANISM COMPRISING VARIANT LYSE AND METHOD OF L-AMINO ACID PRODUCTION USING SAME | June 2022 | October 2025 | Allow | 40 | 2 | 1 | Yes | No |
| 17833695 | MICROORGANISMS AND METHODS FOR ENHANCING THE AVAILABILITY OF REDUCING EQUIVALENTS IN THE PRESENCE OF METHANOL, AND FOR PRODUCING 3-HYDROXYISOBUTYRATE OR METHACRYLIC ACID RELATED THERETO | June 2022 | July 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17832562 | USE OF GLUTAMINE SYNTHETASE FOR TREATING HYPERAMMONEMIA | June 2022 | November 2023 | Allow | 17 | 3 | 0 | Yes | No |
| 17832564 | USE OF GLUTAMINE SYNTHETASE FOR TREATING HYPERAMMONEMIA | June 2022 | February 2025 | Allow | 32 | 5 | 0 | Yes | No |
| 17779642 | METHODS OF REDUCING BIURET IN UREA COMPOSITIONS | May 2022 | May 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17728359 | TARGETED THERAPEUTIC LYSOSOMAL ENZYME FUSION PROTEINS, ASSOCIATED FORMULATIONS AND USES THEREOF | April 2022 | April 2024 | Abandon | 23 | 2 | 0 | No | No |
| 17711993 | Advanced Production of Cannabinoids in Yeast | April 2022 | March 2024 | Allow | 24 | 2 | 1 | Yes | No |
| 17700109 | HIGH EFFICIENCY BASE EDITORS COMPRISING GAM | March 2022 | October 2023 | Allow | 19 | 1 | 1 | No | No |
| 17641802 | METHOD FOR PRODUCING THE SESQUITERPENE VIRIDIFLOROL WITH A FUNGAL ENZYME | March 2022 | June 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17691018 | MAD NUCLEASES | March 2022 | April 2025 | Allow | 37 | 2 | 1 | Yes | No |
| 17640152 | METHODS FOR PRODUCING D-TRYPTOPHAN AND SUBSTITUTED D-TRYPTOPHANS | March 2022 | December 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17635163 | PEROXIDASE ACTIVITY TOWARDS 10-ACETYL-3,7-DIHYDROXYPHENOXAZINE | February 2022 | November 2023 | Allow | 21 | 1 | 1 | No | No |
| 17671001 | Bacterium And Obtaining Method And Application Thereof | February 2022 | December 2023 | Allow | 22 | 2 | 1 | Yes | No |
| 17592869 | ENGINEERED DEOXYRIBOSE-PHOSPHATE ALDOLASES | February 2022 | August 2023 | Allow | 18 | 1 | 1 | No | No |
| 17591514 | CELL-FREE PRODUCTION OF RIBONUCLEIC ACID | February 2022 | October 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17649365 | HETEROLOGOUS PRODUCTION OF 10-METHYLSTEARIC ACID BY CELLS EXPRESSING RECOMBINANT METHYLTRANSFERASE | January 2022 | November 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17583269 | LIPASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME | January 2022 | March 2025 | Abandon | 38 | 5 | 1 | No | No |
| 17578275 | Reverse Transcriptase Mutants with Increased Activity and Thermostability | January 2022 | October 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17571413 | VARIANTS OF CHYMOSIN WITH IMPROVED MILK-CLOTTING PROPERTIES | January 2022 | July 2023 | Allow | 18 | 1 | 1 | No | No |
| 17565684 | PHOTOSYSTEM I-HYDROGENASE CHIMERAS FOR HYDROGEN PRODUCTION | December 2021 | March 2024 | Allow | 26 | 2 | 1 | Yes | No |
| 17566077 | METHODS FOR SAFE AND EFFECTIVE THROMBOLYSIS USING SEQUENTIAL ADMINISTRATION OF TISSUE PLASMINOGEN ACTIVATOR AND MUTANT PRO-UROKINASE | December 2021 | December 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17646437 | RECOMBINANT HOST CELLS FOR THE PRODUCTION OF MALONATE | December 2021 | May 2023 | Abandon | 16 | 0 | 1 | No | No |
| 17597231 | METHOD FOR PRODUCING CYSTEINE FROM GLUTATHIONE | December 2021 | April 2025 | Allow | 40 | 3 | 1 | Yes | No |
| 17559121 | METHOD FOR PRODUCING GALACTOOLIGOSACCHARIDE | December 2021 | March 2023 | Allow | 15 | 1 | 0 | Yes | No |
| 17558454 | T7 RNA POLYMERASE VARIANTS | December 2021 | April 2024 | Allow | 28 | 2 | 1 | No | No |
| 17556504 | Additional Endoglucanase Variants and Methods | December 2021 | January 2024 | Allow | 25 | 2 | 1 | Yes | No |
| 17596878 | BIOCATALYTIC METHOD FOR THE CONTROLLED DEGRADATION OF TERPENE COMPOUNDS | December 2021 | May 2025 | Allow | 41 | 3 | 1 | No | No |
| 17555012 | ENGINEERED URIDINE PHOSPHORYLASE VARIANT ENZYMES | December 2021 | October 2023 | Allow | 22 | 1 | 1 | No | No |
| 17552076 | NOVEL DNA METHYLTRANSFERASE | December 2021 | January 2024 | Abandon | 25 | 2 | 0 | No | No |
| 17550212 | MULTI-SUBSTRATE METABOLISM FOR IMPROVING BIOMASS AND LIPID PRODUCTION | December 2021 | October 2023 | Allow | 22 | 1 | 1 | No | No |
| 17547287 | COMPOSITIONS AND METHODS COMPRISING PROTEASE VARIANTS | December 2021 | August 2024 | Allow | 32 | 2 | 1 | No | No |
| 17543608 | OMEGA-TRANSAMINASE MUTANT OBTAINED BY DNA SYNTHETIC SHUFFLING COMBINED MUTATION AND USE | December 2021 | September 2023 | Abandon | 21 | 2 | 1 | Yes | No |
| 17616843 | METHODS FOR DECOUPLING YIELD AND PRODUCTIVITY OF A NON-CATABOLIC COMPOUND PRODUCED BY A HOST CELL | December 2021 | May 2024 | Allow | 29 | 1 | 1 | No | No |
| 17615856 | MUTATION OF AN ACYL-COA SYNTHASE FOR INCREASED TRIACYLGLYCEROL PRODUCTION IN MICROALGAE | December 2021 | May 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17615807 | FUSION PROTEINS FOR IMPROVED ENZYME EXPRESSION | December 2021 | January 2024 | Abandon | 25 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PAK, YONG D.
With a 28.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 32.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner PAK, YONG D works in Art Unit 1652 and has examined 1,313 patent applications in our dataset. With an allowance rate of 66.4%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 30 months.
Examiner PAK, YONG D's allowance rate of 66.4% places them in the 27% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by PAK, YONG D receive 1.73 office actions before reaching final disposition. This places the examiner in the 37% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by PAK, YONG D is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +21.2% benefit to allowance rate for applications examined by PAK, YONG D. This interview benefit is in the 66% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 28.2% of applications are subsequently allowed. This success rate is in the 51% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 55.6% of cases where such amendments are filed. This entry rate is in the 82% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 36% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 89.9% of appeals filed. This is in the 83% percentile among all examiners. Of these withdrawals, 72.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 71.2% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 9.8% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.1% of allowed cases (in the 62% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.